Pemphigus is a rare autoimmune disorder that affects the skin and mucous membranes. It is characterized by the formation of blisters and erosions on the skin and mucous membranes. The disorder is caused by the production of autoantibodies that attack the desmosomes, which are the structures that hold the cells together. Treatment of pemphigus involves the use of immunosuppressive drugs, such as corticosteroids, to reduce the production of autoantibodies. In some cases, other drugs, such as dapsone, may be used to reduce inflammation.
The pemphigus market is a niche segment of the allergy and immunology market. It is a small but growing market, with a focus on the development of new treatments and therapies for the disorder. The market is driven by the increasing prevalence of pemphigus, as well as the need for better treatments and therapies.
Some companies in the pemphigus market include AbbVie, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Merck, Novartis, Pfizer, and Sanofi. Show Less Read more
